The in vitro cytotoxicity assay indicated that GzmB-encapsulated nanogels had targeted toxicity against CD44-overexpressing HCT-116 cancer cells, while CD44-deficient cells showed little cytotoxic effect. The gene discussed is CD44; the disease is cancer.